We are 7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one CAS:148870-57-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
Related News: After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.1,4-Cyclohexanedimethanol CAS:105-08-8 What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules.4,4'-Dibromo-4''-phenyltriphenylamine CAS:884530-69-2 Our quality control staff then conducts analyses in the testing laboratory to examine whether the API manufactured is ultrapure.Beneficial drug raw materials refer to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs). They are mainly used to meet the needs of original multinational pharmaceutical companies and emerging biopharmaceutical companies for innovative drugs in clinical drug research, registration approval and commercialization sales , Which also contains advanced intermediates used in the manufacture of the drug substance that need to be regulated by regulatory authorities.
Product Name | |
---|---|
4-Fluoro-1H-pyrazole Cas:35277-02-2 | View Details |
9-(3-bromophenyl)carbazole | View Details |
potassium 3-hydroxybutyrate Cas:39650-04-9 | View Details |